Below are our currently enrolling studies for patients with sjogren’s.
Sponsor: Novartis Pharmaceuticals
Protocol Number: CVAY736A22301
The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneously (s.c.) monthly for 52 weeks in adult participants with Sjögren’s disease who have high symptom burden.
Detailed Information:
To learn more or see if you qualify: Click Here